PURPOSE: The feasibility and safety of re-irradiation with carbon ion beams for locally recurrent unresectable pancreatic cancer (URPC) after carbon ion radiotherapy (CIRT) was evaluated. METHODS: Medical records from patients with re-irradiated URPC who were treated with CIRT between November 2017 and February 2019 were reviewed. Inclusion criteria were (1) isolated local recurrence after CIRT, (2) URPC, and (3) tumor located at least 3 mm from the gastrointestinal tract. The first and second CIRT irradiation doses were 55.2 Gy (relative biological effectiveness) in 12 fractions. RESULTS: Ten patients met the inclusion criteria. The median follow-up period was 25.5 months (range, 16.0-69.1) after the first CIRT and 8.9 months (range, 6.4-18.9) after the second CIRT. The median interval between the initial CIRT and the local recurrence was 15.8 months (range, 8.0-50.1). One patient developed grade 3 diarrhea immediately after the second CIRT; no other grade 3 or higher adverse events were attributed to CIRT. The estimated 1-year overall survival, local control, and progression-free survival rates after the second CIRT were 48%, 67%, and 34%, respectively. CONCLUSION: Repeated CIRT is feasible with acceptable toxicity for selected patients with locally advanced URPC after CIRT.
PURPOSE: The feasibility and safety of re-irradiation with carbon ion beams for locally recurrent unresectable pancreatic cancer (URPC) after carbon ion radiotherapy (CIRT) was evaluated. METHODS: Medical records from patients with re-irradiated URPC who were treated with CIRT between November 2017 and February 2019 were reviewed. Inclusion criteria were (1) isolated local recurrence after CIRT, (2) URPC, and (3) tumor located at least 3 mm from the gastrointestinal tract. The first and second CIRT irradiation doses were 55.2 Gy (relative biological effectiveness) in 12 fractions. RESULTS: Ten patients met the inclusion criteria. The median follow-up period was 25.5 months (range, 16.0-69.1) after the first CIRT and 8.9 months (range, 6.4-18.9) after the second CIRT. The median interval between the initial CIRT and the local recurrence was 15.8 months (range, 8.0-50.1). One patient developed grade 3 diarrhea immediately after the second CIRT; no other grade 3 or higher adverse events were attributed to CIRT. The estimated 1-year overall survival, local control, and progression-free survival rates after the second CIRT were 48%, 67%, and 34%, respectively. CONCLUSION: Repeated CIRT is feasible with acceptable toxicity for selected patients with locally advanced URPC after CIRT.
Entities:
Keywords:
carbon ion radiotherapy; local recurrence; locally advanced pancreatic cancer; pancreatic cancer; re-irradiation
Authors: Aaron T Wild; Susan M Hiniker; Daniel T Chang; Phuoc T Tran; Mouen A Khashab; Maneesha R Limaye; Daniel A Laheru; Dung T Le; Rachit Kumar; Jonathan S Pai; Blaire Hargens; Andrew B Sharabi; Eun Ji Shin; Lei Zheng; Timothy M Pawlik; Christopher L Wolfgang; Albert C Koong; Joseph M Herman Journal: J Gastrointest Oncol Date: 2013-12
Authors: Pamela J Boimel; Abigail T Berman; Jonathan Li; Smith Apisarnthanarax; Stefan Both; Kristi Lelionis; Gary L Larson; Ursina Teitelbaum; John N Lukens; Edgar Ben-Josef; James M Metz; John P Plastaras Journal: J Gastrointest Oncol Date: 2017-08
Authors: Philip Sutera; Mark E Bernard; Hong Wang; Nathan Bahary; Steven Burton; Herbert Zeh; Dwight E Heron Journal: Front Oncol Date: 2018-03-07 Impact factor: 6.244
Authors: Eun Sang Oh; Tae Hyun Kim; Sang Myung Woo; Woo Jin Lee; Ju Hee Lee; Sang Hee Youn; Sung Sik Han; Sang Jae Park; Dae Yong Kim Journal: Radiat Oncol J Date: 2018-09-30